Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease

Hadeel Drweesh; Amal Alotaibi; Hussain Abdalghani Alqassim; Mohammed Mustafa Eid; Shaimaa Abdulhadi Emsaad; Mohamed Omar Saad; Alya Salah Higazy; Abdulrahman Alturaiki; Fares Almutairi; Abdulsattar Alhussain; Abdulmohsen Assiri; Hadeel Alkofide; Yazeed Alruthia; Ahmed Albassam; Abdullah Alsultan

doi:10.1007/s44446-026-00063-5

Citations

386

Views

Abstract not available for this publication.

Cite this Article (APA)

Hadeel, D., Amal, A., Hussain, A. A., Mohammed, M. E., Shaimaa, A. E., Mohamed, O. S., Alya, S. H., Abdulrahman, A., Fares, A., Abdulsattar, A., Abdulmohsen, A., Hadeel, A., Yazeed, A., Ahmed, A., Abdullah, A. (2026). Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune disease. Saudi Pharmaceutical Journal. https://doi.org/10.1007/s44446-026-00063-5